HedgeCo.Net — Advent International announced on August 20 a majority investment in New Zealand Clinical Research Group, a clinical-trials operator in New Zealand and Australia. DealStreetAsia, writing from Advent’s statement, said physician shareholders and management, plus existing investor Waterman Capital, will retain a significant minority, with close targeted for the fourth quarter subject to regulatory approvals. BusinessDesk independently reported the majority investment, the Waterman and...
Continue Reading
Sign up for FREE to read the full article and access 153K+ alternative investment headlines.